KalshiVérifier la disponibilitéKYC requis2% de fraisDonnées de résolution vérifiéesGrossièrement calibréProbabilité implicite actuelleOui 98%
Qualite du marche
44 / 100
Faible qualitéVolume 24h
0 €
Liquidité
922,9 €
Faible liquiditéAchat / Vente
80.0% / 86.0%
Spread
6.0 pt
Spread largeDonnées du marché
Mis à jour il y a 22 minutes
17 juin 26, 21:001 janv. 27, 4:59
Tendances
Fonds fictifs uniquement, aucun argent réelCeci n'est pas un conseil financier
Résultat choisi
Yes98%
Tendance du volume
$8123 juil.10j de données26 juil.
Marchés Associés
Hantavirus pandemic in 2026?
91 k €Oui: 3%
POLYMARKET
POLYMARKET
# of views of MrBeast video day 3?
12,9 k €26-27M: 93%POLYMARKET
POLYMARKET
Ebola pandemic in 2026?
4,9 k €Oui: 3%POLYMARKET
POLYMARKET
Measles cases in 2026?
2,9 k €Above 3000: 94%KALSHI
KALSHI
Pandemic in 2026?
2,1 k €Oui: 5%KALSHI
KALSHI
Cyclosporiasis cases reported in the US in 2026?
1,2 k €Above 20k: 34%KALSHI
KALSHIActifs dans ces sujets
Règles
If the FDA's decision on Brepocitinib by Priovant Therapeutics in 2026 is a full approval or an accelerated approval, the market resolves to Yes.
- This market will resolve to No if the FDA's decision is a denial (CRL issued), a withdrawal by the sponsor, or a conditional approval — or if no decision is issued.
- Brepocitinib is an experimental oral pill developed by Priovant Therapeutics that is designed to calm an overactive immune system in people with certain inflammatory diseases.
- Think of it like a circuit breaker for runaway immune signals: it blocks specific molecular switches inside immune cells that, when left unchecked, drive damaging inflammation throughout the body.
- In the VALOR trial , it is being tested as a treatment for dermatomyositis, a rare disease in which the immune system attacks the body's own muscles and skin.